These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 3074131)

  • 21. Breast cancer--which patients?
    Stewart HJ
    Horm Res; 1989; 32 Suppl 1():181-2. PubMed ID: 2613204
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Medroxyprogesterone acetate versus tamoxifen in the therapy of advanced breast cancer.
    Lorenz I; Mechl Z
    Neoplasma; 1985; 32(1):119-24. PubMed ID: 3157070
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The estrogen receptor: a model for molecular medicine.
    Jensen EV; Jordan VC
    Clin Cancer Res; 2003 Jun; 9(6):1980-9. PubMed ID: 12796359
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative binding affinities of tamoxifen, 4-hydroxytamoxifen, and desmethyltamoxifen for estrogen receptors isolated from human breast carcinoma: correlation with blood levels in patients with metastatic breast cancer.
    Fabian C; Tilzer L; Sternson L
    Biopharm Drug Dispos; 1981; 2(4):381-90. PubMed ID: 7317574
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estrogen receptor regulation of quinone reductase in breast cancer: implications for estrogen-induced breast tumor growth and therapeutic uses of tamoxifen.
    Montano MM; Bianco NR; Deng H; Wittmann BM; Chaplin LC; Katzenellenbogen BS
    Front Biosci; 2005 May; 10():1440-61. PubMed ID: 15769636
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Effects and mechanism of action of antiestrogens in breast cancer].
    Borgna JL; Rochefort H
    Sem Hop; 1984 Mar; 60(10):703-9. PubMed ID: 6322320
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer.
    Pyrhönen S; Ellmén J; Vuorinen J; Gershanovich M; Tominaga T; Kaufmann M; Hayes DF
    Breast Cancer Res Treat; 1999 Jul; 56(2):133-43. PubMed ID: 10573106
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of estrogen receptor mutations in tamoxifen-stimulated breast cancer.
    Tonetti DA; Jordan VC
    J Steroid Biochem Mol Biol; 1997 Jun; 62(2-3):119-28. PubMed ID: 9393947
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selective estrogen receptor modulation: the search for an ideal hormonal therapy for breast cancer.
    Dhingra K
    Cancer Invest; 2001; 19(6):649-59. PubMed ID: 11486708
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tamoxifen as sole therapy for primary breast cancer in the elderly patient.
    Foudraine NA; Verhoef LC; Burghouts JT
    Eur J Cancer; 1992; 28A(4-5):900-3. PubMed ID: 1524920
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tamoxifen treatment for breast cancer: concept to gold standard.
    Jordan VC
    Oncology (Williston Park); 1997 Feb; 11(2 Suppl 1):7-13. PubMed ID: 9065921
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
    McKeage K; Curran MP; Plosker GL
    Drugs; 2004; 64(6):633-48. PubMed ID: 15018596
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tales from a targeted therapy.
    Elledge RM
    J Clin Oncol; 2006 Mar; 24(9):1323-5. PubMed ID: 16505410
    [No Abstract]   [Full Text] [Related]  

  • 34. Antiestrogen therapy of breast cancer.
    Lippman ME
    Semin Oncol; 1983 Dec; 10(4 Suppl 4):11-9. PubMed ID: 6367050
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer.
    Jordan VC; Brodie AM
    Steroids; 2007 Jan; 72(1):7-25. PubMed ID: 17169390
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proceedings of the symposium on antiestrogen therapy for hormone-dependent tumors, September 29, 1979, Sorrento, Italy.
    Cancer Treat Rep; 1980; 64(6-7):739-827. PubMed ID: 7427958
    [No Abstract]   [Full Text] [Related]  

  • 37. CYP2D6 and tamoxifen: DNA matters in breast cancer.
    Hoskins JM; Carey LA; McLeod HL
    Nat Rev Cancer; 2009 Aug; 9(8):576-86. PubMed ID: 19629072
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The significance of estrogen receptors in tamoxifen and toremifene therapy.
    Valavaara R; Kangas L
    Ann Clin Res; 1988; 20(5):380-8. PubMed ID: 2975479
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjuvant therapy for breast cancer with positive axillary nodes designed according to estrogen receptor status.
    Rivkin SE; Knight WA; McDivitt R; Cruz T; Foulkes M; Osborne CK; Fabian CJ; Costanzi JJ
    World J Surg; 1985 Oct; 9(5):723-7. PubMed ID: 3840629
    [No Abstract]   [Full Text] [Related]  

  • 40. Reliability of estrogen receptors in predicting response to antiestrogens.
    Valavaara R
    Oncology (Williston Park); 1997 May; 11(5 Suppl 4):14-8. PubMed ID: 9165501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.